Professor Paola Patrignani shares her insights on the advances in the development of therapeutic targets in the platelet for prevention of thrombosis at AHA Scientific Sessions 2025.
Dr. Evan A Stein shares his insights on the emerging opportunities for managing cardiometabolic syndrome at AHA Scientific Sessions 2025.
Professor Eugene Yang shares his insights on the 2025 AHA Blood Pressure Guideline & CKD Management at AHA Scientific Sessions 2025.
Professor Samia Mora explains her opinion on lipid lowering therapies and lipid risk factors at AHA Scientific Sessions 2025.
Professor Debabrata Mukherjee shares his insights on the Guideline for Acute Coronary Syndromes at AHA Scientific Sessions 2025.
Video: https://medicaldigest.org/scientific-contents/interview:new-2025-guideline-acute-coronary-syndromes
Professor Robert O. Bonow shares his insights on aortic regurgitation, imaging, interventions, and the future of treatment at AHA Scientific Sessions 2025.
Professor Cécile Badoual shares her thoughts on the immuno-oncology biomarkers in locally advanced HNSCC and explains the lessons from the KeyNote-689 trial after the ESMO Congress 2025.
Professor Julien Taieb shares his thoughts on the novelties of the treatment of colon cancer at the ESMO Congress 2025.
Video: https://medicaldigest.org/scientific-contents/interview:novelties-treatment-colon-cancer-esmo-2025
Professor Jalid Sehouli explains how to break the wall of platinum-resistance in ovarian cancer at the ESMO Congress 2025.
Professor Thomas B. Powles discuss the results from IMvigor011, a phase 3 trial of ctDNA-guided adjuvant atezolizumab versus placebo in muscle invasive bladder cancer were presented at the ESMO Congress 2025.
Professor Sibylle Loibl shares her thoughts on the additional analyses of DESTINY-Breast09 were presented at the ESMO Congress 2025. Key subgroup analysis of DESTINY-Breast09 confirms efficacy of trastuzumab deruxtecan plus pertuzumab for treating HER2+ advanced or metastatic breast cancer across groups.
Professor Emanuela Romano explains what's new in ESMO guidelines on hepatocellular carcinoma, cutaneous melanoma, Hodgkin Lymphomas and early stage and locally advanced non-small cell lung cancers at the ESMO Congress 2025.
Video: https://medicaldigest.org/scientific-contents/interview:whats-new-esmo-guidelines
Professor Jeanne Tie shares her thoughts on the DYNAMIC-III trial results were presented at the ESMO Congress 2025.
Professor Dirk Schadendorf shares his thoughts on the overcoming therapeutic challenges in high-risk cutaneous squamous cell carcinoma at the ESMO Congress 2025.
Professor Christof Vulsteke shares her thoughts on the data from the phase 3 KEYNOTE-905 trial were presented at the ESMO Congress 2025. A treatment regimen consisting of neoadjuvant enfortumab vedotin-ejfv plus pembrolizumab, radical cystectomy plus pelvic lymph node dissection, and adjuvant EV plus pembrolizumab yielded significant improvements in multiple outcomes in patients with muscle-invasive bladder cancer who are ineligible for or decline cisplatin-based chemotherapy.
Professor Maria De Santis shares her thoughts on the final analysis of the phase 3, open-Label, randomized POTOMAC trial were presented at the ESMO Congress 2025.
Professor Hisham M. Mehanna shares his thoughts on the treatment landscape in resectable LA HNSCC at ESMO 2005 at the ESMO Congress 2025.
Video: https://medicaldigest.org/scientific-contents/interview:treatment-landscape-resectable-la-hnscc
Professor Danny Rischin shares his thoughts on the analysis of second primary cutaneous squamous cell carcinoma tumors reported during the C-POST trial were presented at the ESMO Congress 2025. The study is a randomized phase III study of adjuvant cemiplimab vs placebo for high-risk CSCC.
Professor Irene Burger explains how to unlock the potential of radioligand therapy for advanced prostate cancer at the ESMO Congress 2025.
Prof. Andriani Charpidou co-chaired a very interesting session at this year's ERS congress on lung cancer screening updates.